Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study
Open Access
- 5 October 2026
- journal article
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Abstract
Background: Early case reports and observational studies have suggested an association between isotretinoin and inflammatory bowel disease (IBD). However, large cohort studies and meta-analyses have not demonstrated a meaningful association between isotretinoin use and IBD development. Most prior research has focused on incident IBD risk, with limited attention to disease activity among patients with established IBD. Methods: We conducted a single-center retrospective cohort study of patients with Crohn’s disease (CD) or ulcerative colitis (UC) treated with isotretinoin between 2015 and 2025. Inclusion required at least 1 IBD assessment within the 4 months before and 12 months after isotretinoin initiation. Disease activity was assessed using Harvey–Bradshaw Index (HBI), partial Mayo score (pMS), inflammatory biomarkers, and in some patients, intestinal ultrasound and fecal calprotectin. The primary outcome was composite IBD status change, defined as new clinical activity (Δ ≥ 1 in HBI/pMS), or isotretinoin discontinuation attributed to IBD activity. Results: Thirty-seven patients met inclusion criteria (57% CD, 43% UC). Most patients were in clinical remission at baseline (86%). Following isotretinoin exposure, 92% remained in remission, with no significant changes in HBI, pMS, erythrocyte sedimentation rate, C-reactive protein, or fecal calprotectin. IBD status change occurred in 4 patients (11%), with events largely attributable to underlying IBD-related factors, including biologic transitions, anti-drug antibody development, or medication dose adjustments. Conclusions: Among patients with established, well-controlled IBD, isotretinoin was not associated with clinically meaningful worsening of disease activity, supporting its use in carefully selected patients with stable disease.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
This publication has 9 references indexed in Scilit:
- Prevalence, Age-Distribution, and Impact on Management of Acne in Patients on Upadacitinib for Inflammatory Bowel Disease: Insights from a Single-Center SurveyCrohn's & Colitis 360, 2026
- Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the GastroenterologistAmerican Journal of Gastroenterology, 2024
- Guidelines of care for the management of acne vulgarisJournal of the American Academy of Dermatology, 2024
- Janus Kinase Inhibitors and Adverse Events of AcneJAMA Dermatology, 2023
- Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential AnalysisAmerican Journal of Clinical Dermatology, 2023
- Impact of isotretinoin on inflammatory bowel disease flare in patients with preexisting inflammatory bowel disease diagnosis: A cross-sectional studyJournal of the American Academy of Dermatology, 2022
- Crohn's diseaseThe Lancet, 2017
- Isotretinoin and Risk for Inflammatory Bowel DiseaseJAMA Dermatology, 2013
- Possible Association Between Isotretinoin and Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2006